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Abstract
Tuberculosis (TB) disease in HIV co-infected patients contributes to increased mortality by activating innate and adaptive
immune signaling cascades that stimulate HIV-1 replication, leading to an increase in viral load. Here, we demonstrate that
silencing of the expression of the transcription factor nuclear factor of activated T cells 5 (NFAT5) by RNA interference
(RNAi) inhibits Mycobacterium tuberculosis (MTb)-stimulated HIV-1 replication in co-infected macrophages. We show that
NFAT5 gene and protein expression are strongly induced by MTb, which is a Toll-like receptor (TLR) ligand, and that an
intact NFAT5 binding site in the viral promoter of R5-tropic HIV-1 subtype B and subtype C molecular clones is required
for efficent induction of HIV-1 replication by MTb. Furthermore, silencing by RNAi of key components of the TLR pathway
in human monocytes, including the downstream signaling molecules MyD88, IRAK1, and TRAF6, significantly inhibits MTb-
induced NFAT5 gene expression. Thus, the innate immune response to MTb infection induces NFAT5 gene and protein
expression, and NFAT5 plays a crucial role in MTb regulation of HIV-1 replication via a direct interaction with the viral
promoter. These findings also demonstrate a general role for NFAT5 in TLR- and MTb-mediated control of gene
expression.
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Introduction
Mycobacterium tuberculosis (MTb), the causative agent of tubercu-
losis (TB), is the most common co-infection and cause of death in
patients infected with human immunodeficiency virus type 1
(HIV-1) [1,2]. Direct engagement of pathogen recognition
receptors (PRRs) by MTb on mononuclear phagocytes activates
signaling cascades that directly induce transcription from the
proviral LTR (reviewed in [3]). Furthermore, inflammatory
cytokines and chemokines produced by the human host in
response to MTb infection activate signal transduction pathways
in CD4 T cells and monocytic cells that also result in
transcriptional activation of the HIV-1 LTR [4–6]. Activation of
HIV-1 replication via these MTb-induced pathways ultimately
leads to higher viral loads and, in turn, expedited CD4 T cell loss
and progression to AIDS ([7], reviewed in [8–10]). Furthermore,
the progressive immune compromise associated with HIV-1
infection itself is a major cause of latent MTb reactivation, as
well as increased susceptibility to primary TB infection ([11–15],
reviewed in [8]).
The primary PRR on monocytic cells triggered by MTb
infection is toll-like receptor (TLR) 2 [16–20]. Engagement of
TLR2 results in engagement of the adaptor protein MyD88 and
the subsequent recruitment of several kinases, including IRAK1
and IRAK4, and the ubiquitin ligase TRAF6 ([21–23], reviewed
in [10,24]). TRAF6 activates IkB kinase (IKK) and mitogen-
activated protein (MAP) kinases that, in turn, ultimately induce
activation of specific transcription factor families, including the
NF-kB and AP-1 families, which have been shown to associate
with the HIV-1 LTR and to drive its transcription ([22,25–27],
reviewed in [10]).
Notably, HIV-1 comprises several subtypes, and the LTR of
each subtype is unique with respect to the number and
organization of activator binding sites. For example, HIV-1
subtype B, the most highly characterized viral subtype and the
primary cause of infection in the Americas, Europe, Japan, and
Australia, has two tandem NF-kB motifs in its LTR. By contrast,
HIV-1 subtypes C and E, which have spread disproportionately in
TB-burdened sub-Saharan Africa and southeast Asia, have three
and one NF-kB binding sites, respectively [1,28–30].
We previously showed that the most primordial member of the
nuclear factor of activated T cells (NFAT) family, NFAT5 (also
known as TonEBP), binds to a site within the HIV-1 LTR that is
highly conserved across all HIV-1 subtypes, and is also conserved
in HIV-2 and SIV LTRs. This NFAT5 site overlaps the core NF-
kB binding motifs in the LTR and is required for constitutive
replication of representative HIV-1 subtype B, C, and E isolates in
human primary monocyte-derived macrophages (MDM) [31].
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tionally activated by the MAP kinase p38, which is downstream of
MyD88 signaling, [32], we speculated that NFAT5 may also be
involved in MTb-induced activation of HIV-1 replication via a
TLR-mediated pathway in monocytes and peripheral blood
mononuclear cells (PBMC).
Here, we show that NFAT5 and its cognate binding site are of
crucial importance for efficient MTb-induced stimulation of HIV-
1 replication in human MDM and PBMC. Moreover, we
demonstrate that MTb infection increases NFAT5 gene expression
in human monocytes in a MyD88-dependent manner. Thus, these
results expand the known stimuli of NFAT5 expression to the
PRR-mediated innate immune response, and demonstrate that
NFAT5 is a critical modulator of MTb-induced enhancement of
HIV-1 replication.
Materials and Methods
Ethics statement
In our studies we used unidentified human discarded blood cells
(peripheral blood mononuclear cells, PBMC), which we obtained
from the Blood Bank of Children’s Hospital in Boston.
Cell culture
PBMC from normal unidentified donors were isolated by Ficoll-
Hypaque (Pharmacia Corporation, Peapack, NJ) density gradient
centrifugation and were cultured in RPMI 1640 medium with
2 mM L-glutamine (BioWhittaker, Inc., Walkersville, MD)
supplemented with 10% heat-inactivated fetal calf serum (FCS)
(Gemini Bio-Products, www.gembio.com). Human monocytes
were isolated from PBMC preparations by positive selection with
CD14 microbeads from Miltenyi Biotec (www.miltenyibiotec.com)
as described by the manufacturer, and were cultured at 1610
6
cells per well in 6-well plates in Macrophage-SFM medium
(Gibco, www.invitrogen.com) supplemented with 15 ng/ml re-
combinant human MCSF (R&D, www.rndsystems.com) and 5%
heat-inactivated human AB serum (Nabi, Boca Raton, FL). The
cell cultures were incubated at 37uC and 5% CO2 for 5 days, after
which supernatant was replaced with fresh medium lacking MCSF
before manipulation. More than 95% of the adherent cells
obtained with this technique were CD14+ macrophages as verified
by flow cytometry. THP-1 cells were obtained from ATCC (www.
atcc.org) and cultured in RPMI 1640 medium supplemented with
10% FCS (BioWhittaker, www.lonzabio.com). 293T cells were
obtained from ATCC (www.atcc.org) and were maintained in
Dulbecco’s Modified Eagle’s medium (DMEM) (Gibco, www.
invitrogen.com) supplemented with 10% FCS.
Viruses
HIV-1Bal, HIV-1Lai, HIV-193TH64, HIV-192TH51, HIV-192TH53,
HIV-198CH01, and HIV-198IN22 were obtained from The Central-
ized Facility for AIDS Reagents, National Institute for Biological
Standard and Control (NIBSC), United Kingdom. HIV-1KR25
was isolated in our laboratory as described before [33].
LTR plasmid construction and reporter assay
LTR reporter plasmids were constructed by inserting nucleo-
tides 2208 to +64 relative to the transcriptional initiation site of
HIV-1Lai, HIV-1Bal (B subtype), HIV-198IN17, HIV-198IN22, HIV-
198CH01, HIV-1CM9 (C subtype), HIV-193TH64, HIV-192TH53,
HIV-192TH51, and HIV-1KR25 (E subtype) into the reporter vector
pGL3 (Promega BioSciences, www.promega.com) using Xho I and
Hind III restriction enzyme sites. Sequences were aligned and
analyzed with CLUSTAL W (www.ebi.ac.uk/clustalw/). The
HIV-1Lai NFAT5 binding site-mutant (N5-Mut) reporter plasmid
was created by standard PCR-based mutagenesis methods [34].
THP-1 cells (0.8610
6/ml) were transfected with 0.3 mg/ml LTR
wild-type (WT) or mutated reporter plasmids in combination with
0.03 mg/ml Renilla luciferase (pRL-TK) control vector using
Effectene transfection reagent (Qiagen; www.qiagen.com). Cells
were incubated at 37uC for 16 hours after which they were
stimulated with 10 mg/ml MTb CDC1551 lysate or left unstimu-
lated for 8 hours. Reporter gene expression was quantitated by
dual-luciferase reporter assay according to the manufacturer’s
protocol (Promega; www.promega.com).
Quantitative DNase I footprinting
Recombinant NFAT5 (amino acids 175–471) with an N-
terminal 66 His tag was expressed in E. coli BL21(DE3) cells
(Stratagene; www.stratagene.com) and purified under native
conditions using Ni-NTA agarose (Qiagen). Recombinant p50
and p65 were purchased (Active Motif, www.activemotif.com).
Quantitative DNase I footprinting was performed as previously
described [31].
HIV-1 infectious molecular clones
The plasmid encoding the full-length infectious molecular clone
of HIV-1Lai was obtained from the NIH AIDS Reagent and
Reference Program. The HIV-1Lai/Bal-Env infectious molecular
clone was constructed by replacing the envelope (env) gp160
amino acids 103–717 of the HIV-1Lai (B subtype that utilizes
CXCR4) molecular clone with the corresponding region of HIV-
1Bal (B subtype that utilizes CCR5). The HIV-1Lai/Bal-Env chimeric
virus uses CCR5 as a secondary receptor. The infectious
molecular clone of HIV-198IN22 was constructed using DNA
extracted from PBMC that were infected with a primary isolate of
HIV-198IN22. HIV-1Lai/Bal-Env and HIV-198IN22 mutant viruses
were constructed by introducing point mutations using standard
PCR-based mutagenesis methods.
siRNA transfection of MDM
An siRNA was constructed (Ambion Inc., www.ambion.com) to
target a sequence unique to the NFAT5 transcript: 59-CAA-
CATGCCTGGAATTCAA-39 (nt 335 to 353) [31]. As described,
a control for non-specific siRNA effects, we used an siRNA
targeting the green fluorescent protein (GFP), 59- GGCTACGTC-
Author Summary
The major cause of AIDS deaths globally has been
tuberculosis (TB), which is caused by the bacterium
Mycobacterium tuberculosis (MTb). Co-infection with MTb
exacerbates human immunodeficiency virus type1 (HIV-1)
replication and disease progression via both innate and
adaptive host immune responses to MTb infection. In this
report, we present evidence that the transcription factor
NFAT5 plays a crucial role in MTb-induced HIV-1 replication
in human peripheral blood cells and monocytes. We also
show that MTb infection itself stimulates NFAT5 gene
expression in human monocytes and that its expression
involves the TLR signalling pathway and requires the
downstream adaptor proteins MyD88, IRAK1, and TRAF6.
This identification of a novel role for NFAT5 in TB/HIV-1 co-
infection reveals that NFAT5 is a major mediator of TLR-
dependent gene expression and thus provides a potential
new therapeutic target for treatment of HIV-1 and possibly
other diseases.
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using 1 mM of the indicated siRNA in siPORT NeoFX
transfection reagent (Ambion Inc., www.ambion.com), prepared
as recommended by the manufacturer, in a final volume of 750 ml
in Macrophage-SFM medium plus 5% heat-inactivated human
AB serum. The cultures were left at 37uC overnight after which
cells were washed and incubated in fresh medium. MDM were
transfected two times for efficient knock down of NFAT5
expression before infection experiments were performed [31].
Stable THP-1 cells expressing shRNA
The lentiviral plasmid pLKO.1 expressing shRNA targeting
human MyD88 was purchased from Open Biosystems (www.
openbiosystems.com) and was validated in our laboratory. shRNA
targeting human IRAK1 (forward primer 59-CCGGAG-
CAGCTGTCCAGGTTTCGTCTCATAAAACCTGGACAGC-
TGCTCCTTTTTG-39, reverse primer 59-AATTCAAAAAG-
GAGCAGCTGTCCAGGTTTTATGAGACGAAACCTGGAC-
AGCTGCT-39 mRNA (IRAK1 mRNA target sequence is
underlined) and human TRAF6 (forward primer 59-CCGGA-
GAAACCTGTTGTGATTCGTCTCATAAATCACAACAGG-
TTTCTCCTTTTTG-39, reverse primer 59-AATTCAAAAAG-
GAGAAACCTGTTGTGATTTATGAGACGAATCACAACA-
GGTTTCT-39 (TRAF6 mRNA target sequence is underlined)
were designed in our laboratory and were cloned into the pLKO.1
plasmid. Lentiviruses encoding shRNA sequences were generated
by transfecting the packaging cell line HEK-293T with the shRNA-
encoding pLKO.1 plasmids in combination with the packaging
plasmid psPAX2 and the envelope plasmid pMD2.G using
Effectene transfection reagent (Qiagen, www.qiagen.com). Super-
natants were collected 48 hours post-transfection, clarified by
centrifugation, and stored at 280uC. THP-1 cells were transduced
with the lentiviral particles by culturing the cells with supernatants
from the virus-producing cells in the presence of 8 mg/ml polybrene
(Millipore, www.millipore.com) and spinoculation for two hours at
2000 RPM. Successfully transduced cells were selected and
expanded by treatment with 0.8 mg/ml puromycin.
MTb culture
The MTb clinical strain CDC1551 was prepared by adding
100 ml of frozen bacteria stock into 10 ml of Middlebrook 7H9
medium (Difco BD, www.bd.com) supplemented with albumin
dextrose complex (ADC) and 0.05% Tween 80 (Sigma-Aldrich,
www.sigmaaldrich.com). The cultures were grown to an OD650 of
0.4 at 37uC to ensure that they were in the logarithmic growth
phase. Bacteria were then plated, washed with PBS, resuspended
in PBS, and passed through a 5 mm filter to ensure that the
bacteria were in a single cell suspension. Bacterial cell numbers
were determined by measurement of OD650 before further
dilution with RPMI 1640 medium for cell infection studies at
10:1 PBMC: bacilli or 1:1 MDM: bacilli and THP-1:bacilli.
Colony-forming unit (CFU) analysis was performed and on days 4
and 7 the average CFU counts were 6610
3 and 5610
4,
respectively, confirming that mycobacteria levels increased over
the course of infection of primary MDM.
Western blot
Whole cell extracts were collected with lysis buffer containing
150 mM NaCl, 50 mM Tris–HCl, pH 7.5, 1% Triton, 10%
glycerol, and 1 tablet of Complete EDTA-free Protease Inhibitor
Cocktail (Roche) per 25 ml of buffer. Extracts were boiled for
5 min in 16 Laemmli sample buffer with 5% v/v 2-mercapto-
ethanol and proteins were separated by SDS-PAGE. The gel was
transferred to a nitrocellulose Trans-Blot Transfer Membrane
(BioRad). The blot was then blocked for 1 h at 37uC in a solution
of 4% BSA (Sigma) and 0.1% Tween-20 (BioRad) in a buffer
containing 50 mM Tris and 150 mM NaCl at pH 7.6 (BSA/
TBST). Primary incubation was carried out with a1:200 dilution
of rabbit anti-NFAT5 antibody (H-300) (Santa Cruz Biotechnol-
ogy) and a 1:500 dilution of goat anti-Lamin-B1 antibody (sc-6217;
Santa Cruz Biotechnology) in BSA/TBST for 2 h at room
temperature. The blot was washed 365 min in TBST and
incubated in 1:6000 donkey anti-goat-HRP (Santa Cruz Biotech-
nology) or goat anti-rabbit-HRP (BioRad) as appropriate for 1 h.
The blot was again washed 365 min in TBST and developed with
SuperSignal West Pico Chemiluminescent Reagent (Pierce).
Quantitative PCR
The mRNA expression levels were determined by SYBR
Green-based real-time PCR (Applied Biosystems, www.
appliedbiosystems.com). The reaction conditions were 95uC for
10 min followed by 40 cycles of 95uC for 15 sec and 60uC for
1 min. The results were normalized using b-actin mRNA as an
internal control and expressed as relative values.
Statistical analysis
Where applicable, results are expressed as mean 6 SEM.
Comparison between two groups was performed using the paired
Student t-Test with the aid of Microsoft Excel software. p#0.05
was considered significant.
Results
MTb increases HIV-1 LTR activity of HIV-1 subtypes B, C,
and E
To compare the functional impact of MTb stimulation on
subtype-specific HIV-1 LTR activity, we first constructed reporter
plasmids containing viral subtype B, C, and E LTRs (2208 to
+ 64 nt relative to the transcription start site) linked to the firefly
luciferase reporter gene. After transfection of the monocytic THP-
1 cell line with these plasmids, cells were stimulated with an
irradiated whole cell lysate of MTb (H37Rv). We note that MTb
lysate induces inflammatory responses in monocytes that resemble
those induced in response to live MTb (see for example, [35–37]).
Upon stimulation, the B, C, and E LTR-driven reporters
demonstrated a significant enhancement in luciferase activity
(Figure 1A) and the magnitude of this effect was subtype-specific.
Subtype C LTRs displayed the strongest activity, while the LTRs
from subtype E isolates consistently showed the weakest activity
(Figure 1A), consistent with previous studies demonstrating
subtype-specific LTR activity that used TNF as a stimulus [38,39].
Specific disruption of NFAT5 binding impairs LTR-driven
transcription in THP-1 cells in response to MTb
stimulation
Although the transcription factor NFAT5 binds to a core NF-
kB binding motif in the HIV-1 LTR enhancer region of subtype
B, when two thymines (TT) are changed to cytosines (CC) in the
proximal NF-kB binding motif (named N5-Mut) (bottom of
Figure 1B), the binding of NFAT5 can be disrupted while leaving
binding of NF-kB unperturbed [31]. We examined the require-
ment of NFAT5 for MTb-induced LTR activity by transfecting a
wild-type and NFAT5 mutant LTR reporter construct into THP-1
cells, followed by stimulation with an MTb lysate. As shown in
Figure 1B, in the absence of MTb lysate stimulation the activity of
the NFAT5 binding site-mutant LTR was significantly reduced
(p,0.05) in comparison to the wild-type LTR. When the NFAT5
NFAT5 Modulation of MTb-Induced HIV-1 Replication
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with the MTb lysate, its activity was reduced to an even more
significant extent (p,0.01).
To determine whether MTb lysate stimulation directly
enhances NFAT5 expression in THP-1 cells, we stimulated cells
for 8 or 24 hours or left them unstimulated and examined NFAT5
protein levels by western blot. As shown in Figure 1C, we found
that NFAT5 protein levels steadily increased in response to MTb
lysate stimulation, revealing that TLR engagement by MTb results
in enhanced levels of NFAT5, consistent with its playing a role in
MTb-induced activation of the HIV-1 LTR.
MTb increases NFAT5 mRNA levels in human MDM
Given that macrophages, which are the primary target of MTb
infection, are also a major reservoir of HIV-1 as infection
progresses [40], we next investigated whether MTb is able to
Figure 1. NFAT5 interaction with the LTR is important for MTb-induced HIV-1 transcription. (A) MTb stimulation increases activity of LTRs
derived from HIV-1 subtypes B, C, and E. HIV-1 LTRs (2208 to +64 nt relative to the transcription start site) from representative subtype B, C, and E
viral isolates were cloned into plasmid pGL3. THP-1 cells (0.8610
6/ml) were transfected with each reporter plasmid (0.3 mg/ml) plus the Renilla
luciferase control plasmid pRL-TK (0.03 mg/ml) and incubated at 37uC for 16 hours. Cells were then either left untreated or treated with 10 mg/ml MTb
lysate for 8 hours before termination of the cultures. In the histogram, open bars represent individual LTR activities in untreated cells. Light grey bars
represent mean values of LTR activities from each subtype in untreated cells. Black bars represent individual LTR activities in MTb lysate-treated cells,
and dark grey bars represent mean values of LTR activities from each subtype in cells treated with MTb lysate. LTR transcriptional activity for all of the
representative LTRs tested was significantly increased in cultures treated with MTb lysate in comparison to untreated cultures. Results are from three
independent experiments performed in duplicate (*, p,0.05; **, p,0.01 as compared to unstimulated cultures). (B) Specific disruption of the NFAT5
binding site significantly reduces LTR-reporter gene activity in monocytic cells in response to MTb lysate treatment. THP-1 cells were transfected with
luciferase expression vectors encoding nucleotides 208 to +64 of the wild-type HIV-1Lai LTR and an HIV-1Lai LTR containing the NFAT5 binding site
mutations (N5-Mut). After 16 hours, the cells were left untreated or exposed to 10 mg/ml MTb lysate for 8 hours at 37uC. Disruption of NFAT5 binding
to the enhancer region significantly suppressed LTR-driven reporter gene expression in comparison to the wild-type LTR when cells were treated with
MTb lysate (p,0.01). LTR activity was also suppressed in the untreated cells but to a lesser extent (p,0.05). Results are from three independent
experiments performed in duplicate and adjusted to Renilla luciferase control expression (*, p,0.05; **, p,0.01). Nucleotide sequences representing
the wild-type and NFAT5 binding site-mutated HIV-1Lai LTRs are shown at the bottom of the figure. (C) MTb lysate increases NFAT5 protein levels in
monocytic cells. THP-1 cells were left untreated (control) or exposed to 10 mg/ml MTb lysate for 8 or 24 hours at 37uC. Whole cell extracts were
collected and analyzed by western blot with anti-NFAT5 antibody. An antibody directed against Lamin-B1 was used as a loading control. The
histogram shows densitometric analysis of the NFAT5 bands from the western blot autoradiograph displayed and values represent mean band
intensities at 0, 8, and 24 hours post-stimulation with MTb lysate.
doi:10.1371/journal.ppat.1002620.g001
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MDM. We prepared MDM from five normal donors, stimulated
the cells with the MTb lysate or left them unstimulated, and
measured NFAT5 gene expression levels by quantitative real-time
PCR at 24 and 48 hours. We also investigated whether HIV-1
infection is capable of inducing NFAT5 mRNA synthesis by
infecting MDM with live or heat-inactivated R5-tropic represen-
tatives of subtype B (HIV-1Bal), C (HIV-198IN22), or E (HIV-
192TH64). As shown in Figure 2A, stimulation with MTb lysate
significantly increased NFAT5 mRNA levels at 24 (p,0.05) and
48 (p,0.01) hours, whereas infection with viable or heat-
inactivated HIV-1 isolates did not increase NFAT5 mRNA levels
(Figure 2A). Thus, MTb specifically enhances NFAT5 mRNA
expression in human MDM, and this response continues to
increase for at least 48 hours post-stimulation (Figure 2A).
RNAi directed against NFAT5 inhibits replication of
subtype B HIV-1
To extend the results we obtained in the reporter assays to a
physiological TB/HIV co-infection model, we next tested the
effect of siRNA-mediated ablation of NFAT5 mRNA levels in
MDM co-infected with a subtype B HIV-1Lai infectious molecular
clone and a clinical isolate of MTb. To perform this experiment,
we first constructed an HIV-1Lai clone bearing the CCR5-tropic
envelope region of HIV-1Bal (HIV-1Lai/Bal-env) so that it would
efficiently infect primary MDM. We used this approach to ensure
that our analysis of the roles of NF-kB and NFAT5 in MTb-
induced HIV-1 replication could be interpreted in the proper
context of previous research findings that examined LTR
regulation in the context of full-length viral replication [41–46].
The HIV-1Lai/Bal-Env infectious clone is isogenic for the entire
sequence of the parental HIV-1Lai infectious clone except for the
substitution of the HIV-1Bal envelope co-receptor binding region
in place of the HIV-1Lai envelope co-receptor binding region. We
note that we confirmed that HIV-1Lai/Bal-Env grew in PBMC at a
similar rate to wild-type HIV-1Bal, indicating proper co-receptor
engagement and internalization of this infectious clone (data not
shown).
Next, we knocked down NFAT5 mRNA levels in MDM using
an siRNA that suppresses both NFAT5 mRNA and NFAT5
protein levels [31]. As shown in Figure 2, transfection of the
siRNA specific for NFAT5 reduces NFAT5 mRNA levels in both
MTb-uninfected (p=0.048) and MTb-infected (p=0.021) MDM
as compared to transfection of control GFP siRNA into MTb-
uninfected or -infected MDM (Figure 2B). We note that although
siRNA normally is effective for 48–72 hours in cell lines that
divide rapidly, in human MDM, which are non-dividing cells,
siRNA to host factors remains detectable and functional up to at
least 15 days post-transfection [47].
MDM in which NFAT5 expression had been inhibited with
NFAT5 siRNA or that were transfected with control GFP siRNA
were then infected with 1000 TCID50 of HIV-1Lai/Bal-env. After
overnight virus infection, the cells were then co-infected with the
MTb clinical strain CDC1551. Free virus levels were then
measured in culture supernatants from MDM transfected with
NFAT5-specific siRNA or GFP control siRNA at days 6, 9 and 12
post-HIV-1 infection to measure the impact of NFAT5 inhibition
on MTb-induced HIV replication.
As shown in Figure 2C, HIV-1 replication was suppressed at days
6 and 9 post-infection in the NFAT5 siRNA-treated cells as
comparedtocellstreatedwithcontrolsiRNA,anditwassignificantly
inhibited byday 12 post-infection (p,0.05)(Figure 2C). Thus, knock
down of NFAT5 expression significantly impairs HIV-1 subtype B
replication in MDM co-infected with MTb.
Figure 2. MTb induces NFAT5 gene expression and knockdown of NFAT5 impairs HIV-1 replication during MTb co-infection. (A) MTb
but not HIV-1 increases NFAT5 mRNA synthesis in human macrophages. MDM were isolated from PBMC obtained from four normal donors. The cells
were incubated for 24 or 48 hours with heat-inactivated or live R5-tropic HIV-1 subtype B, C, or E isolates, live MTb strain CDC1551 (1:1 MDM:bacilli),
or left untreated. Quantitative real-time PCR analysis of NFAT5 mRNA expression levels revealed that the low, constitutively present level of NFAT5
mRNA expressed in untreated cells was not affected by exposure to live or inactivated HIV-1, but was significantly increased at both 24 (*, p,0.05)
and 48 (**, p,0.01) hours following infection with MTb. (B) NFAT5-specific siRNA effectively suppresses NFAT5 expression in MDM in both the
absence and presence of MTb co-infection. MDM (1610
6 cells/well in a 6-well plate) from four normal donors were transfected with siRNA specific for
NFAT5 or, as a control, GFP, and were then infected with MTb (1:1 MDM:bacilli) or left uninfected. In the cells transfected with control siRNA, MTb
infection significantly increased NFAT5 expression in comparison to uninfected cells (open bars). When MDM were transfected with NFAT5-specific
siRNA, both constitutively expressed (p=0.048) and MTb-induced (p=0.021) NFAT5 mRNA were significantly suppressed (grey bars). (C) HIV-1
subtype B replication is significantly suppressed in the presence of MTb co-infection when NFAT5 expression is abrogated in human MDM. MDM
from four normal donors were transfected with NFAT5-specific and control siRNAs as described in 2B. Cells were then infected with HIV-1Lai/Bal-env
followed by co-infection with MTb CDC1551. Virus replication was measured at days 6, 9, and 12 post-infection. At day 12, virus replication was
significantly reduced in cells transfected with NFAT5-specific siRNA in comparison to cells transfected with control siRNA (*, p,0.05). We monitored
the morphology of cells within the infected cultures and did not observe noticeable macrophage necrosis even at the final timepoint of viral harvest.
doi:10.1371/journal.ppat.1002620.g002
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specifically disrupted
To demonstrate that the impact of NFAT5 silencing on MTb-
induced viral replication was a direct effect due to modulation of
recruitment of NFAT5 to the HIV-1 LTR and not due to
secondary, NFAT5-regulated effects, we set out to disrupt NFAT5
binding to the viral LTR in the context of HIV-1/MTb co-
infection. This series of experiments also allowed us to dissect the
relative importance of NFAT5 and NF-kB binding to the HIV-1
LTR in MTb regulation of HIV-1 replication.
To perform these experiments, we constructed a panel of
infectious HIV-1Lai/Bal-env molecular clones where either the
NFAT5 site was specifically disrupted or the two NF-kB binding
sites were either individually or dually disrupted (Figure 3A).
Specifically, we constructed a clone in which the NFAT5 binding
site was mutated (named HIV-1Lai/Bal-env-N5-Mut) by changing
the CC dinucleotide to TT in the core NFAT5 binding site and
introduced substitution mutations into the NF-kB/NFAT5 shared
binding element that we predicted would disrupt NF-kB binding
but preserve NFAT5 binding. Specifically, we mutated two
guanines (GG) in the kB I site and changed them to thymine
and adenine (TA) (HIV-1Lai/Bal-env-kB I-mut) and also introduced
the same GG to TA change in the second, more distal NF-kB site
(kB II) in HIV-1Lai/Bal-env (HIV-1Lai/Bal-env-kB II-Mut). We also
created a double NF-kB site mutant virus (HIV-1Lai/Bal-env-kB
I+II-Mut) in order to test the impact of complete disruption of NF-
kB binding to the HIV-1 LTR on MTb regulation.
To determine the specificity of these substitutions upon NFAT5
and NF-kB p50/p65 binding to the LTR, we performed a
quantitative DNase I footprinting analysis using the wild-type
LTR or mutant LTRs in combination with increasing concentra-
tions of recombinant NFAT5 or NF-kB p50/p65 proteins. As
shown in Figure 3B, the N5-Mut LTR could not bind NFAT5
(compare lanes 12–15 and lanes 17–20), but p50/p65 binding was
not impaired (compare lanes 2–5 with lanes 7–10). By contrast,
changing the GG dinucleotide to TA in either NF-kB binding
motif, as predicted, inhibited p50/p65 binding at each site
(compare lanes 2–5 with lanes 7–10 and lanes 12–15 of Figure 3C).
As expected, mutation of both NF-kB sites (kBI +II-Mut) resulted
in abrogation of p50/p65 binding to the LTR. However,
recombinant NFAT5 binding to the single and the double NF-
kB mutant LTRs was not impaired and indeed appeared
enhanced (compare lanes 2–5 to lanes 7–20 of Figure 3D). Thus,
binding of NFAT5 or NF-kB p50/p65 to their respective motifs
can be specifically disrupted within an overlapping or shared
binding site.
NF-kB and NFAT5 binding play independent activating
roles in MTb-mediated induction of HIV-1 replication
We next examined the functional impact of specifically
disrupting NF-kB or NFAT5 binding on regulation of HIV-1
replication by infecting bulk PBMC from four normal donors with
the wild-type or mutant HIV-1Lai/Bal-env molecular clones. After
overnight infection, cells were co-infected with MTb (CDC1551)
or mock-infected and free virus levels were detected by measuring
p24 levels in culture supernatants at days 4, 7, and 12 post-HIV-1
infection.
Replication of each mutant virus was reduced in comparison to
wild-type virus in mock- and MTb-co-infected cells at all
timepoints examined (Figures 4A–4B). As depicted in the
histograms displayed in Figure 4C, at day 12 post-HIV-1 infection
in MTb-co-infected cells there was a significant reduction in levels
of HIV-1Lai/Bal-env-kB I-Mut, HIV-1Lai/Bal-env-kB II-Mut, HIV-
1Lai/Bal-env-kBI +II-Mut, and HIV-1Lai/Bal-env -N5-Mut in com-
parison to wild-type virus (Figure 4C). In the absence of MTb co-
infection, p24 levels were also significantly lower in the PBMC
cultures infected with HIV-1Lai/Bal-env–kB II-Mut, HIV-1Lai/Bal-
env-kBI +II-Mut and HIV-1Lai/Bal-env-N5-Mut, but not HIV-1Lai/
Bal-env-kB I-Mut, in comparison to wild-type virus (Figure 4C).
None of the mutations completely abolished viral induction by
MTb co-infection. However, the replication of each mutant virus
was impaired to a more significant extent in the context of MTb
co-infection, consistent with important roles for both NF-kB and
NFAT5 in MTb-induced HIV-1 replication.
To specifically examine the functional impact of NF-kB and
NFAT5 binding site usage in MDM, which are efficiently infected
by both pathogens, we next isolated MDM from four normal
donors and infected these cells with 1000 TCID50 of wild-type
HIV-1Lai/Bal-env or with the mutant viral clones HIV-1Lai/Bal-env-
kB I-Mut, HIV-1Lai/Bal-env-kB II-Mut, HIV-1Lai/Bal-env-kBI +II-
Mut, or HIV-1Lai/Bal-env-N5-Mut. After overnight incubation, cell
cultures were co-infected with MTb (CDC1551) or left infected
with virus alone. Supernatants were collected at days 4, 7, and 12
post-HIV-1 infection and virus replication was measured. As
shown in Figures 5A and 5C, in the absence of MTb co-infection,
replication of mutant viral molecular clones (HIV-1Lai/Bal-env-kBI -
Mut (p,0.05), HIV-1Lai/Bal-env-kB II-Mut (p,0.01), and HIV-
1Lai/Bal-env-kBI +II-Mut (p,0.01) as well as HIV-1Lai/Bal-env-N5-
Mut (p,0.01) were significantly reduced in comparison to the
wild-type virus (Figures 5A–5C).
When the cultures were co-infected with MTb, p24 levels
increased when the cells were infected with either the wild-type or,
to lower levels, with the kB-I mutant virus (Figure 5B). However,
p24 levels were significantly inhibited in cells infected with HIV-
1Lai/Bal-env -N5-Mut (p,0.01) (Figure 5D). Moreover, p24 levels
were significantly lower at day 12 in cultures infected with HIV-
1Lai/Bal-env-kB II-Mut and HIV-1Lai/Bal-env-kBI +II-Mut as
compared to infection of cells with wild-type virus (Figure 5D).
Notably, although replication of the mutant virus with the single,
proximal NF-kB binding site mutation in the shared NFAT5/NF-
kB element (HIV-1Lai/Bal-env-kB I-Mut) was diminished, this was
not significant at day 12 (Figures 5B–5D).
We note that overall p24 levels were noticeably lower in the
cultures co-infected with MTb compared with those infected with
HIV-1 alone. This is consistent with previous observations
showing that MTb infection of human primary macrophage
cultures ex vivo suppresses HIV-1 infection due to chemokine
synthesis and the enhanced expression of cellular inhibitory factors
[48–50]. Given that NF-kB is efficiently activated in primary
MDM in response to TLR agonists [51] and as we have shown in
Figure 2, NFAT5 gene expression is also induced by TLR
agonists, MDM are a suitable experimental system to analyze the
effect of NF-kB versus NFAT5 binding site mutations on virus
replication in isolated MDM in the absence or presence of MTb
co-infection. Taken together, the results from PBMC and MDM
co-infection experiments demonstrate that the conserved NFAT5
binding site plays as important a transcriptional role in LTR
regulation by MTb as do the NF-kB sites.
NFAT5 is important for enhancement of HIV-1 subtype C
replication in response to MTb infection
As shown in Figure 1, the subtype C LTR was the most active of
the HIV-1 LTR subtypes in the reporter assays. Subtype C LTRs
generally have three functional NF-kB sites in their LTRs, and
subtype C is the predominant viral subtype in the African and
Asian HIV-1 epidemics where MTb co-infection is extremely
common [1,2,28,52]. We thus next extended our analysis of the
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We first constructed an infectious molecular clone of the HIV-1
subtype C primary isolate HIV-198IN22, which has two NFAT5
binding sites in its LTR and three NF-kB sites (Figure 6A). We
disrupted the two NFAT5 binding sites by changing the TT of
each site to CC to create a mutant virus that we named HIV-
Figure 3. Specific disruption of NFAT5 or NF-kB binding sites in the LTR of HIV-1 subtype B. (A) Mutations introduced into a HIV-1Lai/Bal-env
infectious molecular clone. NF-kB and NFAT5 binding site mutations were introduced into the LTR of the HIV-1Lai/Bal-env-wild type (WT) infectious
molecular clone. The NF-kB binding site mutants (HIV-1Lai/Bal-env-kB I-Mut, HIV-1Lai/Bal-env-kB II-Mut, HIV-1Lai/Bal-env-kBI +II-Mut), and NFAT5 binding site
mutant (HIV-1Lai/Bal-env-N5-Mut) are shown along with the HIV-1Lai/Bal-env-WT sequence. Mutations were introduced into the 39 LTR of the HIV-1Lai/Bal-env–
WT proviral sequence. (B) Specific mutation of the NFAT5 binding site abolishes NFAT5 binding to the viral LTR but does not affect NF-kB p50/p65
binding to the overlapping NF-kB binding site. Quantitative DNaseI footprinting analysis is shown using HIV-1 LTR fragments (-262 to +4 nt relative to
the transcription start site) from HIV-1Lai/Bal-env-WT and HIV-1Lai/Bal-env-N5-Mut and increasing concentrations of recombinant NF-kB (p50/p65) (25 ng,
100 ng, and500 ng), or NFAT5(10 ng,50 ng,and250 ng). Theregions that areprotectedfrom DNase I cleavagebythebindingof NF-kB andNFAT5are
indicatedwithabars.(C) SpecificdisruptionoftheHIV-1subtypeBNF-kBbindingsiteseffectivelyabrogates recombinantp50/p65binding.Quantitative
DNaseI footprinting analysis is shown of nucleotides 2262 to +4 from HIV-1Lai/Bal-env-WT, HIV-1Lai/Bal-env-kB I-Mut, HIV-1Lai/Bal-env-kB II-Mut, and
HIV-1Lai/Bal-env-kBI +II-Mut and increasing concentrations of recombinant NF-kB (p50/p65) (25 ng, 100 ng, and 500 ng). The regions that are protected
from DNase I cleavage by the binding of recombinant NF-kB are indicated with a bars. (D) Specific disruption of the HIV-1 subtype B NF-kB binding site
does not inhibit but enhances NFAT5 binding to this region. Quantitative DNaseI footprinting analysis is shown of nucleotides 2262 to +4 from
HIV-1Lai/Bal-env-WT, HIV-1Lai/Bal-env-kB I-Mut, HIV-1Lai/Bal-env-kB II-Mut, and HIV-1Lai/Bal-env-kBI +II-Mut and increasing concentrations of recombinant NFAT5
(10 ng, 50 ng, and 250 ng). The regions that are protected from DNase I cleavage by the binding of recombinant NFAT5 are indicated with a bars.
doi:10.1371/journal.ppat.1002620.g003
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infected overnight with 1000 TCID50 of wild-type HIV-198IN22 or
HIV-198IN22-N5-Mut and the cultures were then co-infected with
MTb CDC1551 or left infected with virus alone. At day 11 post-
viral infection, wild-type HIV-198IN22 replication was greater, but
not significantly so, as compared to replication of HIV-198IN22
NFAT5-Mut (Figure 6B). However, in the context of MTb co-
infection, wild-type HIV-198IN22 replication was significantly
increased (p,0.05) at day 11 over HIV-198IN22 NFAT5-Mut
replication (Figure 6C), indicating that the absence of NFAT5
binding sites was particularly detrimental to virus replication in the
presence of MTb co-infection. Thus, even when three functional
NF-kB binding sites are present in the LTR, as in the HIV-1
subtype C infectious clone studied here, disruption of NFAT5
binding to the LTR impairs virus replication in response to MTb
co-infection.
MTb induces NFAT5 gene expression via the MyD88-
dependent signaling cascade
To begin to decipher the cellular mechanisms underlying
NFAT5-dependent, MTb-induced HIV-1 replication, we next
investigated the requirement for specific signaling molecules in
the TLR pathway that are required for MTb stimulation of
NFAT5 gene expression. We began by examining the require-
ment of TLR2 ligation in enhancing NFAT5 mRNA levels.
When THP-1 cells were treated with the TLR2-specific agonist
Pam3Cys for 16 hours, NFAT5 mRNA levels were significantly
increased in Pam3Cys-stimulated cells as compared to mock-
stimulated control cells (Figure 7A). As a positive control for this
experiment we also infected THP-1 cells with CDC1551
(Figure 7A). Notably, MTb infection enhanced NFAT5 mRNA
levels to a greater extent than Pam3Cys stimulation, suggesting
that additional PRRs may be triggered during actual MTb
infection, augmenting its stimulatory effect on NFAT5 gene
expression (Figure 7A).
The adaptor molecule MyD88 transmits signals upon TLR2
ligation (reviewed in [53]). To confirm that this protein and,
therefore, that this TLR-dependent pathway is important for MTb
induction of NFAT5 gene expression, we constructed a THP-1 cell
line that constitutively expresses a lentivirally-delivered short
hairpin (sh)RNA targeting MyD88. Real-time PCR analysis
demonstrated that MyD88 mRNA levels in these cells were
constitutively and significantly reduced in comparison to control
THP-1 cells transduced with a lentivirus expressing control GFP
shRNA (data not shown). These MyD88 knockdown THP-1 cells
were then infected with MTb (CDC1551) and NFAT5 mRNA
levels were examined. Since TNF is a MyD88-dependent gene
[21,54,55], as a positive control we measured TNF mRNA levels.
For a negative control, we measured mRNA levels of the MyD88-
independent gene CD86 [55,56]. As shown in Figure 7B,
knockdown of MyD88 specifically inhibited MTb-induced NFAT5
and TNF mRNA levels and had no impact on CD86 mRNA
levels. Thus, MTb regulation of NFAT5 is dependent upon
MyD88.
Figure 4. MTb-induced HIV-1 replication in PBMC depends on binding of NFAT5 and NF-kB to the LTR. Specific disruption of the NF-kB
or NFAT5 binding sites in the HIV-1 subtype B LTR inhibits R5-tropic virus replication in human PBMC after co-infection with MTb. PBMC from four
normal donors were infected with 1000 TCID50 HIV-1Lai/Bal-env-WT or the mutants HIV-1Lai/Bal-env-kB I-Mut, HIV-1Lai/Bal-env-kB II-Mut, HIV-1Lai/Bal-env-kB
I+II-Mut, or HIV-1Lai/Bal-env-N5-Mut and either; (A) left untreated, or (B) co-infected with MTb isolate CDC1551 (10:1 cells:bacilli). Viral p24 levels in
culture supernatants were measured at days 4, 7 and 12 post-infection. (C) Histograms show viral p24 levels at day 12 in the MTb uninfected (grey
bars) and MTb co-infected (black bars) PBMC cultures. Replication of the mutant viruses was compared to wild-type virus replication under the same
experimental conditions (without and with MTb co-infection, respectively). *, p,0.05; **, p,0.01, as compared to HIV-1Lai/Bal-Env-WT.
doi:10.1371/journal.ppat.1002620.g004
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NFAT5 transcription, we also constructed THP-1 cells transduced
with lentivirally-delivered shRNAs targeting IRAK1 or TRAF6,
two signaling molecules downstream of MyD88. As shown in
Figures 7C and 7D, knockdown of both IRAK1 and TRAF6
significantly inhibited MTb induced NFAT5 mRNA levels. As
expected, MTb-induced TNF gene expression was also signifi-
cantly reduced (Figures 7C–7D), consistent with a role for IRAK1
and TRAF6 in TNF gene expression secondary to MTb infection
as previously reported. Although CD86 gene expression did not
depend on MyD88 (Figure 7B), abrogation of IRAK1 and TRAF6
gene expression significantly reduced CD86 mRNA levels,
indicating that CD86 expression is IRAK1- and TRAF6-
dependent, but MyD88-independent in MTb-infected monocytes
(Figures 7C–7D). Taken together, these results clearly demonstrate
that MTb upregulation of NFAT5 gene expression in human
monocytic cells requires activation of MyD88 and the MyD88-
associated adaptor molecules IRAK1 and TRAF6.
Discussion
The transcription factor NFAT5 is the most evolutionarily
divergent member of the Rel family of NFAT proteins [57]. Unlike
the other NFAT proteins (NFATp, NFATc, NFAT3, and NFAT4),
NFAT5 binds DNA as an obligate dimer in a fashion resembling
NF-kB proteins [58], is calcineurin independent, and does not
cooperate with the basic region-leucine zipper proteins Fos and Jun
in gene activation ([59,60], reviewed in [61–63]). To date, osmotic
stress, integrin activation, and T cell-stimulation have been shown
to regulate NFAT5 activity [59,64,65]. Based on our demonstration
here that the host innate immune response to MTb infection
induces MyD88-dependent upregulation of NFAT5 gene expres-
sion, we have expanded this list to include MTb as an additional
stimulus. We have linked this observation to MTb-stimulated HIV-
1 gene expression by showing that MTb enhances the replication of
HIV-1 subtypes B and C via a direct interaction between NFAT5
andthe viralpromoter.Thus,HIV-1hasco-optedNFAT5,whichis
induced as part of the innate immune response to TB, for enhanced
viral transcription/replication.
NF-kB is activated after MTb engagement of PRRs [20,66].
Multiple studies of HIV-1 activation have shown that initial
recruitment of the NF-kB p50/p65 heterodimer to the HIV-1
proviral enhancer region is crucial for HIV gene transcription
(reviewed in [67,68]). Upon interaction with the viral LTR, NF-kB
rapidly induces hyperacetylation of histones associated with
nucleosome 1 (nuc-1) at the HIV-1 transcription start site,
resulting in recruitment of the pTEFb complex, which is required
for RNA pol II processivity ([69], reviewed in [68,70]).
In this report we directly examined the relative roles of NFAT5
and NF-kB p50/p65 in HIV-1 replication under conditions of
activation by MTb co-infection, when NF-kB levels in the nucleus
are elevated. We found that specific disruption of the NFAT5
binding site(s) in R5-tropic subtype B or subtype C infectious
molecular clones significantly reduced virus replication in PBMC
or MDM co-infected with a clinical isolate of MTb. Thus, NF-kB
binding to the viral LTR is not sufficient to compensate for the loss
of NFAT5 binding to the LTR under conditions of MTb co-
infection. Reciprocally, an intact NFAT5 site could not compen-
sate for disruption of the two NF-kB sites. Thus, both factors are
required for MTb-induced HIV-1 replication.
Figure 5. Disruption of NF-kB or NFAT5 sites in the LTR inhibits MTb-induced HIV-1 replication in MDM. MDM from four normal donors
were infected with 1000 TCID50 of HIV-1Lai/Bal-env–WT or the mutants HIV-1Lai/Bal-env-kB I-Mut, HIV-1Lai/Bal-env-kB II-Mut, HIV-1Lai/Bal-env-kBI +II-Mut, or
HIV-1Lai/Bal-env-N5-Mut, and were either (A) left infected with virus alone or (B) co-infected with MTb CDC1551 (1:1 MDM:bacilli). Viral p24 levels in the
culture supernatants were measured at days 4, 7 and 12 post-infection. Presentation of viral p24 levels at day 12 in cultures infected with (C) HIV-1
alone or (D) co-infected with MTb are shown as histograms. (*, p,0.05; **, p,0.01, as compared to HIV-1Lai/Bal-env–WT).
doi:10.1371/journal.ppat.1002620.g005
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infection, disruption of NF-kB site II consistently resulted in
greater suppression of virus replication than disruption of NF-kB
site I. Consistent with these findings, synthetic reporter assays have
previously shown that these two sites have distinct roles in driving
transcription. The downstream NF-kB site I binding site, which is
directly upstream of three highly conserved Sp binding sites,
appears to enhance Sp protein recruitment to the LTR [71–73].
Because NF-kB site I overlaps the NFAT5 binding site, it is
possible that loss of NF-kB binding to this site is mitigated, at least
in part, by increased NFAT5 binding to the mutated site. This
hypothesis is consistent with our quantitative DNase I footprinting
analysis that shows that specific disruption of NF-kB site I results
in enhanced binding of NFAT5 to the LTR.
HIV-1 subtype C now makes up greater than 50% of all HIV-
1 infections worldwide, and its prevalence is especially high in
regions of endemic TB [1,2,28,52], Most HIV-1 subtype C
isolates possess three NF-kB binding sites in the LTR [30]. Our
analysis of MTb whole lysate-stimulated, LTR-driven reporter
gene expression from representative B, C, and E LTRs showed
that LTRs derived from subtype C isolates were superior in
driving reporter gene expression as compared to LTRs derived
from subtype B or E isolates. Other studies have found that, in
response to TNF, subtype C LTRs drive reporter gene
transcription more strongly than other subtype LTRs [38,39].
In the co-infection model utilized in this report, in which clinical
isolates of both MTb and HIV-1 subtype C were used to infect
freshly prepared human peripheral blood cells, we found that
specific disruption of NFAT5 binding to the LTR significantly
impaired viral replication during MTb co-infection, indicating
that even the presence of three intact NF-kB binding sites, which
is typical for HIV-1 subtype C isolates [30], cannot compensate
for loss of NFAT5 recruitment to the viral LTR in the context of
MTb co-infection.
Given that the NF-kB and NFAT5 binding motifs overlap, how
do NF-kB and NFAT5 function at this overlapping or shared site
in the LTR to drive viral transcription in response to MTb
infection? Because NFAT5 expression continues to rise for at least
48 hours post-MTb infection (Figure 2A), one possibility is that the
host factors NF-kB and NFAT5 associate with the LTR at
different stages after viral activation. While NF-kB presence in the
nucleus declines in the hours post MTb infection [74,75], NFAT5
levels escalate. Thus, NFAT5, which is pivotal for HIV-1
transcription in unstimulated cells [31], may, after Mtb infection,
perpetuate viral transcriptional initiation begun by NF-kB and,
with Tat levels also elevated, promote high levels of sustained
HIV-1 transcription. Indeed, in response to hypertonic stress,
NFAT5 binds to the aldose reductase (AR) promoter and induces
rapid hyperacetylation of histones H3 and H4 [76]. Furthermore,
hypertonic stress of mouse renal collecting duct epithelial cells
results in NFAT5 and NF-kB complex formation at NF-kB-
dependent gene promoters [77]. Thus, there are precedents for
imagining that NFAT5 could function at the HIV-1 LTR by
inducing histone remodeling in a manner similar to NF-kB ([69],
reviewed in [68,70]) or by directly interacting with NF-kBi na
cooperative manner.
Figure 6. Disruption of the NFAT5 site in HIV-1 subtype C significantly impairs MTb-induced viral replication. (A) Mutation of the
NFAT5 binding site in an HIV-1 subtype C infectious molecular clone. NFAT5 binding site mutations were introduced into the LTR of subtype C HIV-
198IN22-WT. The NFAT5 binding site mutant (HIV-198IN22 N5-Mut) LTR sequence is shown alongside that of HIV-198IN22-WT. The HIV-198IN22 isolate
analyzed here contains three NF-kB and two NFAT5 binding sites. The unique 39 terminal adenine, which is important for NFAT5 binding to its site, is
shown in blocks. Mutations were introduced into the 39 LTR of the HIV-198IN22-WT proviral sequence. PBMC from four normal donors were infected
with 1000 TCID50 of HIV-198IN22–WT or HIV-198IN22-N5-Mut. Cells were then (B) left infected with virus alone or (C) co-infected with MTb strain
CDC1551 (10:1 cells:bacilli). Culture supernatants were collected at days 3, 7 and 11 post-infection and viral p24 levels were measured. Replicationo f
HIV-198IN22-N5-Mut was significantly reduced at day 11 post-infection in comparison to HIV-198IN22–WT (*, p,0.05) in the presence of MTb co-
infection.
doi:10.1371/journal.ppat.1002620.g006
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PLoS Pathogens | www.plospathogens.org 10 April 2012 | Volume 8 | Issue 4 | e1002620Figure 7. The MyD88-mediated signaling cascade is important for MTb induction of NFAT5 expression in human monocytes. (A)
Engagement of TLR2 significantly enhances NFAT5 mRNA synthesis in monocytes. THP-1 cells were incubated with the TLR2-specific ligand Pam3Cys
(5 mg/ml), infected with MTb strain CDC1551 (1:1 cells:bacilli), or left untreated. After 16 hours, NFAT5 mRNA levels were measured. NFAT5 mRNA
expression was significantly increased when the cells were incubated with Pam3Cys (*, p,0.05) or infected with MTb (**, p,0.01). (B) MyD88 is
important for MTb induction of NFAT5 gene expression in human monocytes. THP-1 cells that constitutively express lentivirally-delivered shRNA
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PLoS Pathogens | www.plospathogens.org 11 April 2012 | Volume 8 | Issue 4 | e1002620In conclusion, we have demonstrated that NFAT5 is required
for the replication of R5-tropic subtype B and subtype C HIV-1
isolates in response to MTb-co-infection of human PBMC and
MDM. Functional NF-kB interaction with the viral LTR is also
required, but fully intact NF-kB binding elements are unable to
compensate for the loss of NFAT5 recruitment to the viral
promoter. In addition, we have demonstrated that MTb infection
or stimulation with the TLR2 ligand PAM3Cys, induces NFAT5
gene expression in human monocytes. Furthermore, we have
shown that MTb stimulation of NFAT5 depends on TLR pathway
signaling molecules, including MyD88, IRAK1, and TRAF6.
Taken together, the findings presented here enhance the general
understanding of the innate immune response to MTb infection by
showing that NFAT5 is a major mediator of TLR-dependent gene
expression; its importance for gene regulation is likely applicable to
other MTb- and TLR-regulated genes. Moreover, these data
provide molecular insights into MTb regulation of HIV-1
transcription, thereby elucidating several new targets for thera-
peutic interventions aimed at controlling TB/HIV-1 co-infection.
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